Pura Vida Group

Historically, endometrial cancer was categorized primarily by its appearance under a microscope.

By 2026, the clinical standard has shifted to a molecular classification system based on The Cancer Genome Atlas (TCGA). Patients are now grouped into four distinct categories: POLE-mutated (ultramutated), Mismatch Repair Deficient (dMMR), Copy-Number Low, and Copy-Number High (p53-abnormal). This genomic fingerprint is more predictive of a patient's survival and response to treatment than traditional staging alone. For instance, women with POLE mutations often have an excellent prognosis regardless of tumor size, allowing for less aggressive surgical interventions, whereas those with p53 mutations are identified early for intensive chemotherapy and targeted agents.